By Sriparna Roy
January 23, 2026 – 8:14 AM PST
(Reuters) – Novo Nordisk’s (NOVOb.CO) Wegovy pill was prescribed more than 18,000 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race, according to analysts who cited IQVIA data.
Investors are closely watching prescriptions data to see if the Danish drugmaker can press its first-mover advantage against rival Eli Lilly (LLY.N) in a competitive weight-loss market.
Oral obesity treatments offer patients greater flexibility and a needle-free alternative, although injectable medications are still expected to dominate for years to come.
At least two analysts…



